Literature DB >> 35030798

Single-Chromophore-Based Therapeutic Agent Enables Green-Light-Triggered Chemotherapy and Simultaneous Photodynamic Therapy to Cancer Cells.

Ming Liu1, Jiaqi Meng1, Weier Bao1, Siyuan Liu1, Wei Wei2, Guanghui Ma2, Zhiyuan Tian1.   

Abstract

A new type of single-chromophore-based photoactivatable prodrug (B-Cbl-3) enabling green-light-triggered chemotherapy and simultaneous photodynamic therapy with superb therapeutic efficacy was developed by conjugating a photoactive BODIPY derivative with an antitumor chlorambucil moiety. The optimized BODIPY moiety markedly enabled high efficient photogeneration of 1O2 and fluorescence emission with distinct colors before and after photorelease of chlorambucil. The preliminary biological experiment results have verified the efficient photorelease of chlorambucil from B-Cbl-3 and the huge contrast in cytotoxicity between them, superior combined therapeutic performance based on extraordinary low doses of drug and light irradiation, and ratiometric fluorescence imaging for in situ monitoring drug release. The salient superiority of B-Cbl-3 regarding alleviating the attenuation of triggering light caused by optically turbid tissue that short-wavelength lights typically encounters has also been verified.

Entities:  

Keywords:  cancer; chemotherapy; combined therapy; photodynamic therapy; visible light

Year:  2019        PMID: 35030798     DOI: 10.1021/acsabm.9b00356

Source DB:  PubMed          Journal:  ACS Appl Bio Mater        ISSN: 2576-6422


  2 in total

1.  Photoresponsive prodrug-dye nanoassembly for in-situ monitorable cancer therapy.

Authors:  Kaiqi Long; Yifan Wang; Wen Lv; Yang Yang; Shuting Xu; Changyou Zhan; Weiping Wang
Journal:  Bioeng Transl Med       Date:  2022-03-12

2.  Photouncaging of Carboxylic Acids from Cyanine Dyes with Near-Infrared Light.

Authors:  Hana Janeková; Marina Russo; Urs Ziegler; Peter Štacko
Journal:  Angew Chem Int Ed Engl       Date:  2022-06-01       Impact factor: 16.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.